Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly/Sankyo prasugrel enters Phase III

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Lilly/Sankyo's antiplatelet agent prasugrel (CS-747) is slated to begin Phase III trials by year-end. TRITON-TIMI-38 will compare prasugrel to Plavix in 13,000 acute coronary syndrome patients undergoing percutaneous coronary intervention. Prasugrel is designed to prevent platelet activation by blocking adenosine diphosphate receptors on platelet surfaces...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS002704

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel